Rebecca Zash

Maternal and Fetal Outcomes in Mice Following Exposure to Dolutegravir Alone or in Combination with Lamivudine or Tenofovir Disoproxil Fumarate/Emtricitabine

Abstract Background and Aims Dolutegravir (DTG)-based regimens are widely used in HIV treatment, including during pregnancy, but the contribution of the nucleoside reverse transcriptase inhibitor (NRTI) backbone on maternal and foetal outcomes remains unclear. We examined this in...